CJC-1295 with DAC vs Vesugen
Well Studied vs Moderate Research
synergistic Mechanism-based · 47% CJC-1295 with DAC and Vesugen work through complementary pathways. Growth hormone signaling supports tissue repair processes. A well-established combination in recovery protocols.
Molecular Data
CJC-1295 with DAC Vesugen
Weight 3,647.28 Da 390 Da
Half-life 6-8 days Not established
Chain 30 amino acids 3 amino acids
Type GHRH analog with DAC Tripeptide bioregulator
Key Benefits
CJC-1295 with DAC
01 Convenient weekly dosing
02 Sustained GH/IGF-1 elevation
03 6-8 day half-life
04 Significant body composition changes
Vesugen
01 Protects vascular system from aging effects
02 Limits atherosclerosis development
03 Decreases endothelial cell dysfunction
04 Activates SIRT1 anti-aging pathway
05 Enhances stem cell proliferation
06 Reduces cellular senescence markers
07 Reverses SASP phenotype
08 Works synergistically with Cardiogen
Dosing Protocols
CJC-1295 with DAC
1-2mg weekly / Once or twice weekly (e.g., Monday/Thursday for split dosing)
Conservative Anti-Aging 1mg Once weekly
Standard Protocol 2mg Once weekly
Split Dosing 1mg Twice weekly (Mon/Thu)
Loading Protocol 2mg first week, then 1mg Weekly
Vesugen
10-20 mg per day (oral capsules) or 10 mg (injectable) / Daily for 10-20 consecutive days (Khavinson bioregulator cycle)
Research protocol 10 mg Daily for 10 days
Side Effects
CJC-1295 with DAC
Water retention
Joint pain
Carpal tunnel symptoms
Vesugen
Generally well-tolerated
Minimal side effects reported
Contraindications
Diabetes history
Cancer history
Predisposed sleep apnea
Active cardiovascular emergencies (seek medical care)
Known hypersensitivity
Pregnancy or breastfeeding
Research Evidence
CJC-1295 with DAC Vesugen
Status Well Studied Moderate Research
References 4 studies 3 studies
Latest 2025 —
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.